Skip to main content Skip to footer

AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2

By

The antiviral drug molnupiravir received regulatory approval for treating people … Continued

Learning and confirming in publicly funded antiviral trials

By

Reporting the phase 2 results from the UK AGILE CST-2 … Continued

First antiviral pill to treat Covid-19 approved in UK

By

A “game-changing” antiviral pill that is part of the AGILE … Continued

AGILE Covid-19 drug testing platform opens new trial in South Africa

By

A new international trial to assess whether high doses of … Continued

First patient dosed in latest stage of AGILE COVID-19 drug trial

By

LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine, and the NIHR Southampton Clinical Trials Unit at the University of Southampton today announced the first-ever patient dosed in the latest trial of potential new treatments for SARS-CoV-2 as part of the UK’s COVID-19 drug testing platform, AGILE.

People across the south to be part of pioneering research in the fight against COVID-19

By

People across the south are being asked to play their part in helping vital research into new COVID-19 treatments.
A ground-breaking clinical trial platform being led by researchers at the Southampton Clinical Trials Unit is now recruiting patients through the NIHR Southampton Clinical Research Facility within the General Hospital.

Groundbreaking COVID-19 treatments to be fast-tracked through clinical trials

By

The world’s most innovative treatments for COVID-19 will soon be … Continued

Government funding boost for COVID-19 drug testing platform

By

The AGILE drug testing platform has received a multi-million pound award from the UK government’s Department of Health and Social Care to fast track the clinical trials of innovative treatments against COVID-19.

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19

By

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) … Continued

Agile Press release: Two new therapies to be tested in ground-breaking COVID-19 clinical trial

By

GlaxoSmithKline and Vir Biotechnology have joined forces with researchers from the Universities of Liverpool and Southampton, who are leading an accelerated early phase trials platform to test new treatments for COVID-19. The two monoclonal antibody therapies, VIR-7831 and VIR-7832, will be given to patients who have tested positive for COVID-19 and have mild or moderate symptoms. Pre-clinical studies have already shown that these antibody therapies have promising results in combatting coronavirus infections. The hope is that, by conducting early phase human trials, the researchers will discover whether they could be an effective tool for treating patients with the COVID-19 in the future.